Amgen's Q1 earnings call highlighted reduced revenues and a lowered full-year revenue guidance due to macroeconomic challenges, particularly impacting Enbrel sales. While management maintained EPS guidance through cost-cutting measures and expressed optimism about their pipeline, the negative impact on key products and cautious outlook are likely to weigh on investor sentiment in the short term.

[-1]